Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01562873
Title Ruxolitinib in Patients With Breast Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

breast cancer

triple-receptor negative breast cancer

Therapies

Ruxolitinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.